Protein toxins: intracellular trafficking for targeted therapy.
about
Shiga toxin receptor Gb3Cer/CD77: tumor-association and promising therapeutic target in pancreas and colon cancerSyntaxin 16 and syntaxin 5 are required for efficient retrograde transport of several exogenous and endogenous cargo proteinsImmunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent CancersShiga Toxins as Multi-Functional Proteins: Induction of Host Cellular Stress Responses, Role in Pathogenesis and Therapeutic ApplicationsBithionol blocks pathogenicity of bacterial toxins, ricin, and Zika virusIn vitro intracellular trafficking of virulence antigen during infection by Yersinia pestis.Preparation of biocompatible heat-labile enterotoxin subunit B-bovine serum albumin nanoparticles for improving tumor-targeted drug delivery via heat-labile enterotoxin subunit B mediation.In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer.Temperature and cholera toxin B are factors that influence formation of membrane nanotubes in RT4 and T24 urothelial cancer cell lines.Different types of cell death induced by enterotoxins.Intracellular delivery system for antibody-Peptide drug conjugatesIdentification of agents effective against multiple toxins and viruses by host-oriented cell targeting.Challenges in design and characterization of ligand-targeted drug delivery systems.Entry and killing of Tetrahymena thermophila by bacterially produced Shiga toxinIdentification of amino acids important for binding of Clostridium perfringens epsilon toxin to host cells and to HAVCR1.A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicityAlternate routes for drug delivery to the cell interior: pathways to the Golgi apparatus and endoplasmic reticulum"Alternative" endocytic mechanisms exploited by pathogens: new avenues for therapeutic delivery?Retrograde traffic in the biosynthetic-secretory route.Shiga toxin as a bacterial defense against a eukaryotic predator, Tetrahymena thermophila.Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy.Protein toxins from plants and bacteria: probes for intracellular transport and tools in medicine.Verotoxin-1 treatment or manipulation of its receptor globotriaosylceramide (gb3) for reversal of multidrug resistance to cancer chemotherapy.Ribosome-inactivating proteins with an emphasis on bacterial RIPs and their potential medical applications.EHDs meet the retromer: Complex regulation of retrograde transport.α-sarcin and RNase T1 based immunoconjugates: the role of intracellular trafficking in cytotoxic efficiency.Heat-induced transcription of diphtheria toxin A or its variants, CRM176 and CRM197: implications for pancreatic cancer gene therapy.Passage through the Golgi is necessary for Shiga toxin B subunit to reach the endoplasmic reticulum.Co-application of ricin A chain and a recombinant adenovirus expressing ricin B chain as a novel approach for cancer therapy.Saporin as a novel suicide gene in anticancer gene therapy.Intracellular trafficking of Shiga-toxin-B-subunit-functionalized spherulites.Correlation between Shiga toxin B-subunit stability and antigen crosspresentation: a mutational analysis.Preparation of an engineered safer immunotoxin against colon carcinoma based on the ribotoxin hirsutellin A.Subcellular drug targeting, pharmacokinetics and bioavailability.Biochemical, pathological and oncological relevance of Gb3Cer receptor
P2860
Q21090050-EFF6C1CB-56A8-4DE8-B0CD-C5192BB5B364Q24301008-CFB6727F-1BCD-4044-93C0-BEC27F3E4081Q26751473-8B4CA1F0-CE7A-4C51-80EF-DE83C78F7DC3Q26752966-A2BBEFD9-7957-413B-928C-C84B9490A538Q27468627-9C4720EF-32F4-406E-A56F-B7ED6A5E4DF7Q33483363-0D7F32A1-0B4C-4E4D-896B-738FFA191AD7Q33599486-BB6D0852-482B-4FC3-9C3E-FDD45AD2FA85Q34080906-EFA43DA1-7C24-474E-8F39-68CFB983FF58Q34176125-B9256C47-0A3D-40CD-82A3-FA9992288613Q35155921-CF158C83-6E3A-4C73-971C-3793B61A020AQ35594851-7CD4DA6A-5355-4AD8-804C-2EA16E51A03EQ35999412-F56AD3A8-2381-48AE-A7EE-FEC46AC96B58Q36346851-45FE8914-FFB8-4F4A-89BF-9250534CBEBAQ36492970-4785948E-B35D-4264-BA64-47DBC1CDD4F8Q36501314-88C8BF3C-F85C-426D-96F4-A7534636DA49Q36536466-1C071613-E99A-496B-BA67-DDE4161E27E0Q36899294-AE985460-B9B4-4F6F-B790-35D531EDA62FQ36913900-BA367033-8345-4EEA-80DD-FB856A86A72AQ37083291-990E56CB-1CE0-4FAF-B6C6-C66A1C87216FQ37301976-0F2B8D10-F4A1-4A36-8071-28D008B05577Q37334787-EE0A8682-F7E9-41F9-818E-BB1C4C60DFA2Q37729388-09E5B1DC-F3C9-4B0E-844F-EBF374E18D5DQ37954271-C0571F44-DA8B-43DE-B892-6C8748B998EBQ38019016-E654E0A2-DB8A-43E9-9385-492925C0C1F9Q38062535-1B3C4F11-02BF-4F8A-9640-7DD2A1001920Q38932236-6AEA2EAE-0A1E-4D72-AD26-0B2EC9111404Q39824358-B23E1289-840C-4710-9AE0-AC4F43413301Q39883425-7477D263-7351-40DC-82D8-4EFF25D1389EQ40144780-9F4D0087-62DE-4978-B672-DC767BBB5F23Q45862855-4B6AE52A-702F-45C7-B2A9-DC80D978E73AQ46531930-966B6459-A44A-4BB6-AACF-8B1A06C7AF7CQ46857270-ED8A8C55-83E4-450F-84FE-B8D92EBEB1CFQ53296795-7B24E117-FAD5-4E58-A9F6-4C25D18F1FD6Q54665069-F1A98F2E-233F-4765-AE9C-30A8605C65B7Q57117659-554C461E-9FC0-4FBE-A930-23FB79DFECB2
P2860
Protein toxins: intracellular trafficking for targeted therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Protein toxins: intracellular trafficking for targeted therapy.
@ast
Protein toxins: intracellular trafficking for targeted therapy.
@en
type
label
Protein toxins: intracellular trafficking for targeted therapy.
@ast
Protein toxins: intracellular trafficking for targeted therapy.
@en
prefLabel
Protein toxins: intracellular trafficking for targeted therapy.
@ast
Protein toxins: intracellular trafficking for targeted therapy.
@en
P2860
P356
P1433
P1476
Protein toxins: intracellular trafficking for targeted therapy
@en
P2093
Decaudin D
P2860
P2888
P304
P356
10.1038/SJ.GT.3302557
P577
2005-09-01T00:00:00Z